GT200600213A - Metodos para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios - Google Patents

Metodos para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios

Info

Publication number
GT200600213A
GT200600213A GT200600213A GT200600213A GT200600213A GT 200600213 A GT200600213 A GT 200600213A GT 200600213 A GT200600213 A GT 200600213A GT 200600213 A GT200600213 A GT 200600213A GT 200600213 A GT200600213 A GT 200600213A
Authority
GT
Guatemala
Prior art keywords
methods
syntheize
cianoquinolins
intermediaries
substituted
Prior art date
Application number
GT200600213A
Other languages
English (en)
Inventor
Warren Chew
Gloria Karen Cheal
Jacqueline Francesca Lunetta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37037465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600213A publication Critical patent/GT200600213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA INVENCIÓN SE REFIERE A MÉTODOS PARA PRODUCIR 3-CIANOQUINOLINAS SUSTITUIDAS, QUE INCLUYEN LOS COMPUESTOS DE ACUERDO CON LA SIGUIENTE FÓRMULA (IV), DICHOS MÉTODOS SON ADECUADOS PARA LA PRODUCCIÓN A GRAN ESCALA, ADEMÁS EVITA EL USO DE SEPARACIONES CROMATOGRÁFICAS, Y SE OBTIENE UN PRODUCTO ESTABLE DE PUREZA ELEVADA, EN FORMA MÁS EFICIENTE QUE EN LA TÉCNICA ANTERIOR.
GT200600213A 2005-05-25 2006-05-22 Metodos para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios GT200600213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68439105P 2005-05-25 2005-05-25

Publications (1)

Publication Number Publication Date
GT200600213A true GT200600213A (es) 2007-01-12

Family

ID=37037465

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600213A GT200600213A (es) 2005-05-25 2006-05-22 Metodos para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios

Country Status (19)

Country Link
US (1) US20060270668A1 (es)
EP (1) EP1883631A1 (es)
JP (1) JP2008545688A (es)
KR (1) KR20080016671A (es)
CN (1) CN101203494A (es)
AR (1) AR053872A1 (es)
AU (1) AU2006249600A1 (es)
BR (1) BRPI0610147A2 (es)
CA (1) CA2609186A1 (es)
CR (1) CR9544A (es)
GT (1) GT200600213A (es)
IL (1) IL187532A0 (es)
NO (1) NO20076067L (es)
PA (1) PA8676201A1 (es)
PE (1) PE20061417A1 (es)
RU (1) RU2007143161A (es)
TW (1) TW200716557A (es)
WO (1) WO2006127207A1 (es)
ZA (1) ZA200710148B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100408579C (zh) * 2001-02-24 2008-08-06 贝林格尔英格海姆法玛两合公司 黄嘌呤衍生物,其制法及其作为药物组合物的用途
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
AU2013202912B2 (en) * 2007-06-08 2016-10-27 Firmenich Incorporated Modulation of chemosensory receptors and ligands associated therewith
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2016225895B2 (en) * 2007-10-17 2018-02-08 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
AU2013203571B2 (en) * 2007-10-17 2016-06-16 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof
JP2009215259A (ja) * 2008-03-12 2009-09-24 Ube Ind Ltd ３−ハロゲノ−４−ヒドロカルビルオキシニトロベンゼン化合物の製造方法
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
KR101577159B1 (ko) 2008-07-31 2015-12-11 세노믹스, 인코포레이티드 단맛 향상제의 제조 방법 및 중간체
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN101723854A (zh) * 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR20200003933A (ko) * 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102718679B (zh) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 一种诺那替尼关键中间体的制备方法
CN102718749A (zh) * 2011-03-30 2012-10-10 北京德众万全药物技术开发有限公司 抗肿瘤药物诺那替尼的制备方法
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2879554A1 (en) 2012-08-06 2014-02-13 Senomyx, Inc. Substituted 4-amino-1h-2,1,3-benzothiadiazine 2,2-dioxide compounds and their use as sweet flavor modifiers
CN103588755B (zh) * 2012-08-17 2016-06-22 正大天晴药业集团股份有限公司 Neratinib的制备方法
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN103265530A (zh) * 2013-06-14 2013-08-28 苏州明锐医药科技有限公司 来那替尼的制备方法
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN105367552A (zh) 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法
CN105461689B (zh) * 2015-05-19 2018-12-04 上海麦步医药科技有限公司 一种表皮生长因子受体(egfr)抑制剂来那替尼的新型制备方法
CN105085485B (zh) * 2015-08-21 2017-08-29 哈尔滨珍宝制药有限公司 一种来那替尼的制备方法
CN105330646B (zh) * 2015-12-04 2019-05-24 上海勋和医药科技有限公司 一种抗肿瘤药马来酸来那替尼的制备方法
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN105949176B (zh) * 2016-06-24 2018-10-26 浙江海正药业股份有限公司 一种来那替尼的纯化方法
US20200308141A1 (en) 2016-06-27 2020-10-01 Pliva Hrvatska D.O.O. Solid state forms of neratinib and salts thereof
CN106220560A (zh) * 2016-07-27 2016-12-14 华侨大学 一种多取代喹啉衍生物的制备方法
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP2021503506A (ja) * 2017-11-20 2021-02-12 テリジーン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ． （ｅ）−ｎ−（３−シアノ−７−エトキシ−４−（（４−フェノキシフェニル）アミノ）キノリン−６−イル）−４−（ジメチルアミノ）ブタ−２−エンアミドのマレイン酸塩及びその結晶形態
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
CN110357854A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼的制备方法
CN108373467A (zh) * 2018-04-27 2018-08-07 江苏创诺制药有限公司 来那替尼游离碱晶型及制备方法
SG11202100846YA (en) 2018-08-07 2021-02-25 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
CN109320686B (zh) * 2018-08-29 2021-06-08 华南理工大学 一种聚异脲类聚合物及其制备方法和应用
CN112679473B (zh) * 2019-10-18 2024-03-05 四川科伦药物研究院有限公司 来那替尼中间体晶体、制备方法及其用途
CN111875539B (zh) * 2020-07-15 2022-06-21 苏中药业集团股份有限公司 一种egfr类分子靶向抗肿瘤药物的制备方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
CN111848582A (zh) * 2020-08-19 2020-10-30 重庆医科大学 制备表皮生长因子受体抑制剂来那替尼有关物质的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1117659B1 (en) * 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
MXPA04007495A (es) * 2002-02-05 2004-11-10 Wyeth Corp Proceso para sintesis de acidos n-acil2-amino-4-alcoxi-5-nitrobenzoicos.
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
MXPA06001590A (es) * 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
AU2003304497B2 (en) * 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
UA85698C2 (ru) * 2004-01-16 2009-02-25 Уайет Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения

Also Published As

Publication number Publication date
AR053872A1 (es) 2007-05-23
PE20061417A1 (es) 2007-01-20
PA8676201A1 (es) 2009-03-31
CA2609186A1 (en) 2006-11-30
IL187532A0 (en) 2008-03-20
AU2006249600A1 (en) 2006-11-30
CN101203494A (zh) 2008-06-18
NO20076067L (no) 2007-12-21
JP2008545688A (ja) 2008-12-18
EP1883631A1 (en) 2008-02-06
ZA200710148B (en) 2008-09-25
KR20080016671A (ko) 2008-02-21
TW200716557A (en) 2007-05-01
CR9544A (es) 2008-03-07
RU2007143161A (ru) 2009-07-10
US20060270668A1 (en) 2006-11-30
WO2006127207A1 (en) 2006-11-30
BRPI0610147A2 (pt) 2010-06-01

Similar Documents

Publication Publication Date Title
GT200600213A (es) Metodos para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
CR11827A (es) Activadores de glucoquinasa
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
CR8360A (es) 1,3 dimetilbutilcarboxanilidas
ECSP099327A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso
CR9113A (es) Compuestos acetamida como fungicidas
CY1114287T1 (el) Νεα πυραζολο-4-ν-αλκοξυκαρβοξαμιδια ως μικροβιοκτονα
CY1109471T1 (el) Μεθοδοι και μεσα για την παραγωγη υαλουρονανης
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
SG10201811715YA (en) Intermediates and methods for the synthesis of halichondrin b analogs
UY31674A1 (es) Derivado heterocíclico fusionado y su uso
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
CY1117461T1 (el) Παραγωγα κιναζολινοδιονης, παρασκευη αυτων και οι θεραπευτικες εφαρμογες τους
TN2010000064A1 (en) Novel herbicides
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
AR064165A1 (es) Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
EA200701592A1 (ru) Композиты и способы их получения и использования
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
AR054735A1 (es) Proceso de obtencion de un derivado de piperazina
CY1118583T1 (el) Σταθερες δοσολογικες μορφες ανθελονοσιακων σπιρο και δισπιρο 1,2,4-τριοξολανιων
SV2010003501A (es) Fungicidas novedosos
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
CY1111954T1 (el) Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη